Based on proprietary ionizable lipid-like compound libraries, the R&D teams create
LNP carriers that:
![]() |
Allow for an efficient and targeted delivery of mRNA therapeutics to the organs of interest, such as the lungs, livers and injured vascular wall; |
![]() |
Demonstrate excellent biocompatibility, suggesting that they are safe for potential clinical use; |
![]() |
Possess high transfection efficiency; |
![]() |
Are applicable to various routes of medication. |